A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
A form of economic evaluation comparing the costs of alternative interventions that have equal effects.
In Health care, Cost-minimisation analysis (CMA) is an economic appraisal that determines the least costly alternative therapy after the proposed drug has been established to be no more detrimental than its main competitor(s) in terms of capability and toxicity.
See also:
Cost–benefit analysis
Cost-effective (healthcare economics)
Cost-effectiveness league table (healthcare economics)
Cost-effectiveness threshold (health economics)
Cost consequences analysis (CCA)
Balanced Scorecard, Click tracking, Cost leadership, List price, British National Formulary (BNF), National Institute for Health and Clinical Excellence (NICE), Interventions - clinical, American Medical Association (AMA), Trend analysis, Concept development and testing, Disease mongering, National Service Frameworks (NSF), Prescription only medicine (POM), Global Health Observatory , Sensitivity analysis (pharmacoeconomics),
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...